- Home
- EAF vs CRMD Comparison
EAF vs CRMD Comparison
Compare EAF & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | CRMD |
|---|---|---|
| Founded | 1886 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.4M | 509.9M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EAF | CRMD |
|---|---|---|
| Price | $7.73 | $7.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $11.75 | ★ $15.20 |
| AVG Volume (30 Days) | 215.8K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | ★ $504,134,000.00 | $311,709,000.00 |
| Revenue This Year | $4.25 | $0.30 |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | ★ N/A | $3.59 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $0.55 | $6.13 |
| 52 Week High | $20.32 | $17.43 |
Technical Indicators
Market Signals| Indicator | EAF | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 60.97 |
| Support Level | $7.65 | $6.14 |
| Resistance Level | $7.73 | $7.44 |
| Average True Range (ATR) | 0.64 | 0.24 |
| MACD | 0.28 | 0.11 |
| Stochastic Oscillator | 87.21 | 91.44 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.